Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

Group 1 - The company announced that its product, Sidabenamine tablets (Epidaza), has been included in the National Medical Insurance Directory under regular Class B management, effective January 1, 2026 [1][3] - The inclusion of Sidabenamine in the National Medical Insurance Directory is expected to enhance patient access to medication and stabilize the pricing system for innovative drugs [3] - The product is classified under the insurance payment scope for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and for untreated diffuse large B-cell lymphoma (DLBCL) patients when used in combination with R-CHOP [1][2] Group 2 - Sidabenamine is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and has been approved for various cancers in different regions, including PTCL and DLBCL in mainland China, and adult T-cell leukemia in Japan [2] - The company has pioneered the licensing of innovative drugs from China to Europe and the United States, marking a significant milestone in the industry [2]

证券代码：688321 证券简称：微芯生物 公告编号：2025-082 深圳微芯生物科技股份有限公司 自愿披露关于公司产品纳入国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 2025年12月7日，根据国家医保局、人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生 育保险药品目录》（以下简称"《国家医保目录》"）以及《商业健康保险创新药品目录》（2025年）的 通知【医保发〔2025〕33号】。深圳微芯生物科技股份有限公司（以下简称"公司"）产品西达本胺片 （爱谱沙?）纳入《国家医保目录》常规乙类管理。现将相关信息公告如下： 医保支付范围：1.既往至少接受过一次全身化疗的复发或难治的外周T细胞淋巴瘤(PTCL)患者；2.联合 R-CHOP(利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松)用于MYC和BCL2表达阳性的既往未经 治疗的弥漫大B细胞淋巴瘤(DLBCL)患者。 二、药品相关情况 西达本胺（商品名"爱谱沙?/Epidaza?"）是全球首个亚型选择性组蛋白去乙酰化酶（HDAC）抑制剂， 开创 ...

Group 1 - Heng Rui Pharmaceutical has 9 drugs included in the national medical insurance directory for the first time, with an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 [5] - Junshi Biosciences' products Tuoyi® and Junshida® have been added to the national medical insurance directory, enhancing patient affordability and market promotion [6] - Huadong Medicine's subsidiary has products included in the national medical insurance and commercial insurance innovative drug directories, expected to aid in market promotion [7] Group 2 - Aidi Pharmaceutical's two innovative HIV drugs have successfully renewed their inclusion in the national medical insurance directory, with specific reimbursement prices set [8] - Fuxing Pharmaceutical has multiple products newly included in the national medical insurance directory, which is anticipated to positively impact future performance [9] - Weichuang Biotechnology's product has been included in the national medical insurance directory, which is expected to enhance market promotion and sales [10] Group 3 - Muxi Co., Ltd. announced a final online issuance rate of 0.03348913% after the mechanism was activated, with a total of 22.83 million shares issued [2] - Doushan New Materials reached a consensus on production reduction in the BOPET industry, although the sustainability of long-term price increases remains uncertain [2] - Guanglian Aviation's controlling shareholder has had the detention lifted, allowing normal operations to resume [3] Group 4 - Jiangjian Co., Ltd. clarified that it bears no obligations for any overdue financial products related to its controlling shareholder, confirming normal operations [4] - Tian Ci Materials' controlling shareholder has committed not to reduce holdings, holding 34.35% of the shares [13] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [14]

微芯生物公告称，2025年12月7日，公司产品西达本胺片（爱谱沙®）纳入《国家医保目录》常规乙类 管理，编号932。医保支付范围包括复发或难治的外周T细胞淋巴瘤等患者。西达本胺是全球首个亚型 选择性组蛋白去乙酰化酶抑制剂，已在多地获批多项适应症。新版《国家医保目录》2026年1月1日起执 行，预计不会对本报告期经营业绩产生重大影响。 ...

Core Points - Microchip Biotech (688321) announced on December 7 that its product, Sidabenamine Tablets (Aipusha), has been included in the National Medical Insurance Directory under regular Category B management [1] Group 1 - The inclusion of Sidabenamine Tablets in the National Medical Insurance Directory is a significant development for the company [1] - This decision is based on the notice issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the updated drug directories for basic medical insurance and commercial health insurance [1]

自愿披露关于公司产品纳入国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 12 月 7 日，根据国家医保局、人力资源社会保障部关于印发《国家 基本医疗保险、工伤保险和生育保险药品目录》（以下简称"《国家医保目录》"） 以及《商业健康保险创新药品目录》（2025 年）的通知【医保发〔2025〕33 号】。 深圳微芯生物科技股份有限公司（以下简称"公司"）产品西达本胺片（爱谱沙®） 纳入《国家医保目录》常规乙类管理。现将相关信息公告如下： 证券代码：688321 证券简称：微芯生物 公告编号：2025-082 深圳微芯生物科技股份有限公司 本次公司产品西达本胺片纳入《国家医保目录》常规乙类管理，有利于维持 原创新药价格体系稳定性、提高患者用药可及性，也体现了国家医保局对原创新 药临床价值的认可与支持。新版《国家医保目录》将于 2026 年 1 月 1 日起正式 执行，预计不会对公司本报告期的经营业绩产生重大影响。敬请广大投资者谨慎 决策，注意防范投资风险。 特此公告。 一、产品纳入《国家医保目录 ...

Core Insights - The 20th "EY Entrepreneur Of The Year" awards were announced, recognizing 12 outstanding entrepreneurs from mainland China and Hong Kong/Macau, emphasizing innovation and commitment to the private economy in the new era [1] - The theme of this year's awards is "Twenty Years of Unwavering Original Intent, Building Dreams in the New Era," highlighting the importance of technology and innovation in driving business success [1] - The awards align with China's 14th Five-Year Plan, focusing on high-level technological self-reliance and the development of new productive forces [1][2] Group 1: Award Significance - The awards serve as a platform for entrepreneurs to exchange ideas and collaborate, reflecting the pulse of national economic development [2] - The event took place in Hong Kong, leveraging its unique position as a gateway for mainland companies to expand internationally [2] - The recognition of entrepreneurs is crucial for promoting new productive forces and supporting the construction of a modern economic system in China [2][3] Group 2: Industry Representation - Award winners come from various sectors, including technology, life sciences and healthcare, manufacturing, and services, all demonstrating innovation through technology [1][3] - The private economy has become an indispensable force in driving high-quality economic development and deepening global economic cooperation [3] - The implementation of the "Private Economy Promotion Law" in May aims to create a stable and transparent legal environment for private enterprises [3] Group 3: Notable Winners - In the technology sector, notable winners include: - Chen T, CEO of Shenzhen Yuntian Lifei Technology Co., Ltd. - Che, CEO of Yunzhisheng Intelligent Technology Co., Ltd. - Guijia Ya, Chairman of Simu Technology [5] - In the manufacturing sector, winners include: - Ge Jiang, Chairwoman of Weisheng Information Technology Co., Ltd. - Li Peiliang, Chairman of Dongjiang Group (Holdings) Limited [6] - In the life sciences and healthcare sector, Lu Xianping, Founder and CEO of Shenzhen Microchip Biotechnology Co., Ltd., was recognized [8]

证券代码：688321 证券简称：微芯生物 公告编号：2025-081 深圳微芯生物科技股份有限公司 关于召开职工代表大会暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"或"微芯生物"）于 2025 年 12 月 5 日召开 2025 年职工代表大会第二次会议。会议通过了如下事项： 一、免去何杰先生、金霞女士公司职工代表监事职务 根据《中华人民共和国公司法》（以下简称"公司法"）《深圳微芯生物科技 股份有限公司章程》（以下简称"《公司章程》"）等相关规定，公司不再设置监事 会。因此，免去何杰先生、金霞女士公司职工代表监事职务。何杰先生、金霞女 士仍将继续在公司担任其他职务。 何杰先生、金霞女士担任公司职工代表监事期间恪尽职守、勤勉尽责，为公 司规范运作和健康发展发挥了积极作用，公司对其表示衷心感谢！ 二、选举何杰先生为公司职工代表董事 根据《公司法》《公司章程》等相关规定，公司董事会中设立一名职工代表 董事。2025 年职工代表大会第二次会议选举何杰先 ...

上海 SHANGHAI hana Board Middle 上海市通力律师事务所关于深圳微芯生物科技股份有限公司 2025 年第一次临时股东大会的法律意见书 致:深圳微芯生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受深圳微芯生物科技股份有限公司(以下简 称"公司")的委托,指派本所郭珣律师、赵伯晓律师(以下简称"本所律师")根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律、法规和规范 性文件(以下统称"法律法规")及《深圳微芯生物科技股份有限公司章程》(以下简称"公司 章程")的规定就公司 2025年第一次临时股东大会(以下简称"本次股东大会")相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有 签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有 效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及 ...